NASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Price, News & Analysis $5.23 -0.28 (-5.08%) Closing price 04:00 PM EasternExtended Trading$5.32 +0.09 (+1.63%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Aligos Therapeutics Stock (NASDAQ:ALGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aligos Therapeutics alerts:Sign Up Key Stats Today's Range$5.21▼$5.6050-Day Range$4.99▼$7.6552-Week Range$3.98▼$13.69Volume60,554 shsAverage Volume41,378 shsMarket Capitalization$32.64 millionP/E RatioN/ADividend YieldN/APrice Target$38.50Consensus RatingModerate Buy Company Overview Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases and other viral infections. The company’s research programs are designed to address significant unmet needs in conditions including chronic hepatitis B virus (HBV) infection, hepatitis D virus (HDV) infection and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis. Aligos’ pipeline includes investigational therapies intended to target different stages of disease biology. Its HBV programs include capsid assembly modulators, such as ALG-000184, which are designed to interfere with the virus’s replication cycle. The company has also developed ALG-055009, an oral thyroid hormone receptor beta agonist being evaluated for potential use in MASH. Aligos has pursued additional antiviral research, including programs directed at coronaviruses and other viral diseases. Founded in 2018, Aligos Therapeutics is headquartered in South San Francisco, California. The company conducts research and clinical development through collaborations and clinical studies intended to support the advancement of its investigational medicines in global markets. Its programs remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.AI Generated. May Contain Errors. Read More Aligos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreALGS MarketRank™: 2.62058089105 of 5 starsAligos Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 586th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAligos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAligos Therapeutics has a consensus price target of $38.50, representing about 636.1% upside from its current price of $5.23.Amount of Analyst CoverageAligos Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aligos Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($6.81) to ($5.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aligos Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.31% of the float of Aligos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 14.35, which indicates bearish sentiment.Change versus previous monthShort interest in Aligos Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.91 News SentimentAligos Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aligos Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for ALGS on MarketBeat in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Aligos Therapeutics is held by insiders.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aligos Therapeutics' insider trading history. Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALGS Stock News HeadlinesAligos Therapeutics, Inc. (ALGS) - What Are Researchers Saying About This Stock?October 12 at 4:15 AM | americanbankingnews.comAligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026October 6, 2026 | marketscreener.comMFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 14 at 1:00 AM | Weiss Ratings (Ad)Aligos Therapeutics To Present HBV, HDV Programs At AASLD 2026October 6, 2026 | rttnews.comAligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026October 5, 2026 | globenewswire.comAligos Therapeutics Amends Long-Term Headquarters Lease AgreementSeptember 15, 2026 | tipranks.comAligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company UpdatesSeptember 2, 2026 | finance.yahoo.comAligos Therapeutics to Present at the Cantor Global Healthcare ConferenceSeptember 2, 2026 | globenewswire.comSee More Headlines ALGS Stock Analysis - Frequently Asked Questions How have ALGS shares performed this year? Aligos Therapeutics' stock was trading at $9.32 at the start of the year. Since then, ALGS shares have decreased by 43.9% and is now trading at $5.23. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($1.09) by $0.95. The firm had revenue of $27.78 million for the quarter, compared to analysts' expectations of $24.68 million. Aligos Therapeutics had a negative trailing twelve-month return on equity of 160.72% and a negative net margin of 241.01%. When did Aligos Therapeutics' stock split? Aligos Therapeutics shares reverse split before market open on Monday, August 19th 2024.The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Aligos Therapeutics IPO? Aligos Therapeutics (ALGS) raised $150 million in an initial public offering on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aligos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Senti Biosciences (SNTI), Boeing (BA), Stem (STEM), Advanced Micro Devices (AMD), Coherus Oncology (CHRS) and Gossamer Bio (GOSS). Company Calendar Last Earnings8/06/2026Today10/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ALGS's financial health is in the Yellow zone, according to TradeSmith. ALGS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALGS CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees82Year Founded2018Price Target and Rating Average Price Target for Aligos Therapeutics$38.50 High Price Target$50.00 Low Price Target$20.00 Potential Upside/Downside+636.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($7.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.19 million Net Margins-241.01% Pretax Margin-230.81% Return on Equity-160.72% Return on Assets-92.30% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$2.19 million Price / Sales14.90 Cash FlowN/A Price / Cash FlowN/A Book Value$8.67 per share Price / Book0.60Miscellaneous Outstanding Shares6,240,000Free Float5,758,000Market Cap$32.64 million OptionableNo Data Beta2.36 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ALGS) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALGS Stock Alerts